ENGAGE-XR
1.10.2021 08:02:08 CEST | Business Wire | Press release
US e-commerce entrepreneur, and founder and CEO of CommerceHub, Frank Poore has been appointed as a Non-executive Director of leading virtual reality ('VR') technology company, ENGAGE XR Holdings plc (“ENGAGE XR”).
Frank brings a wealth of entrepreneurial and business experience to ENGAGE XR with over 25 years as an e-commerce innovator and visionary. As founder and CEO of CommerceHub, Frank built an industry-leading company that enables $30 billion in recurring e-commerce sales for 15,000 of the world’s largest retailers, brands, distributors, and marketplaces.
Based in Europe, ENGAGE XR (which is changing its name from VR Education Holdings plc) is listed on the London Stock Exchange. ENGAGE XR is focused on becoming a leading global provider of virtual communications solutions through its proprietary software platform, ENGAGE. ENGAGE provides users with a platform for creating, sharing, and delivering VR content for communication, training, and online events. The Company has announced the development of a new fully featured corporate metaverse, codenamed "ENGAGE Oasis", with the launch expected in the first half of 2022.
In the first six months of 2021, the Company’s revenue increased by 83% to €1.25 million as demand for VR as a communications tool, was accelerated by the pandemic. Since ENGAGE’s launch in 2019, the number of commercial customers has increased to over 130, as well as the Company making significant progress in the roll-out of ENGAGE in China through its partnership with HTC and entering the Middle East for the first time. ENGAGE customers include Abbott Laboratories, BMW Motorsport, Facebook, HTC, MongoDB, and the US State Department.
As well as serving on the Board, Frank will work with the management of ENGAGE XR to help expand the Company’s sales function to help achieve its goal of becoming a leading global provider of virtual communications and support the successful roll-out of ENGAGE Oasis.
As CEO, Frank led CommerceHub through enormous periods of growth, resulting in major milestone events including international expansion, two significant acquisitions, and a successful public floatation on Nasdaq. CommerceHub’s platform and business model were also highly respected for generating industry-leading EBITDA returns. Frank created four successful liquidity events for CommerceHub shareholders - first through a sale of CommerceHub to QVC/Comcast Corporation in 2006, second via public offering in 2016 on Nasdaq, third through a $1 billion take-private sale of CommerceHub to GTCR and Sycamore Partners in 2018, and most recently through a majority sale to Insight Partners and Goldman Sachs for nearly $2 billion in December 2020.
David Whelan, CEO of ENGAGE XR, commented: “With over 25 years’ experience as a successful entrepreneur, building a company with a strong sales and technology focus, and a track record of delivering value for global multinational businesses, Frank is a major addition to our Board. His experience will be invaluable as we expand our ENGAGE metaverse offering particularly in North America working together to achieve our ambitious medium and long-term growth targets.”
Frank Poore said: “I am excited to join the Board of VRE and to work with VR pioneers like David and Sandra. As companies embrace remote work, they will need new ways to manage their culture and team chemistry. ENGAGE is already well-positioned as the “office of the future” by enabling distributed teams to come together into a virtual office, conference room, auditorium, classroom, or coffee shop to create a sense of presence and to foster collaboration, creativity, and serendipity. The development of ENGAGE Oasis is especially exciting and it can establish itself as the go-to virtual world where global organizations come to interact with each other, and their stakeholders. I believe that my background and personality will bring a disruptive yet collaborative spirit that can help unlock substantial value for shareholders.”
Website: https://www.engagexrholdings.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
